Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 4, 2007, Pages 439-445

  Lin, Jing ^a   Yan, Xiao Jun ^a   Chen, Hai Min ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Anti angiogenesis; CAM; Fascaplysin; HUVEC; VEGF

Indexed keywords

CYCLIN DEPENDENT KINASE 4 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; FASCAPLYSIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CAPILLARY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL STRAIN; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; CELL LINE; CELL PROLIFERATION; CHORIOALLANTOIC MEMBRANE; CYCLIN-DEPENDENT KINASE 4; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846269340     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0282-x     Document Type: Article

References (23)

1. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH (1994) Mutations and altered expression of p16INK4A in human cancer. Proc Natl Acad Sci USA 91(23):11045-11049
2. Kim H, Ham EK, Kim YI, Chi JG, Lee HS, Park SH, Jung YM, Myung NK, Lee MJ, Jang JJ (1998) Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas. Cancer Lett 131(2):177-183
3. Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD (2001) Cell cycle and biochemical eVects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 276(20):16617-16623
4. Garrett MD, Fattaey A (1999) CDK inhibition and cancer therapy. Curr Opin Genet Dev 9(1):104-111
5. Roll DM, Ireland CM, Lu HSM, Clardy J (1988) Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp. J Org Chem 53:3276-3278
6. Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B (2000) Inhibition of cyclindependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Commun 275(3):877-884
7. Radchenko OS, Novikov VL, Elyakov GB (1997) A simple and practical approach to the synthesis of the marine sponge pigment fascaplysin and related compounds. Tetrahedron Lett 38:5339-5342
8. Huwe A, Mazitschek R, Giannis A (2003) Small molecules as inhibitors of cyclin-dependent kinases. Angew Chem Int Ed Engl 42(19):2122-2138
9. Senderowicz AM (2003) Small-molecule cyclin-dependent kinase modulators. Oncogene 22(42):6609-6620
10. Klagsbrun M, Moses MA (1999) Molecular angiogenesis. Chem Biol 6:217-224
11. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M (1996) Clinical signiWcance of vascular endothelial growth factor and basic Wbroblast growth factor gene expression in liver tumor. Hepatology 23:455-464
12. Richardson M, Singh G (2003) Observations on the use of the avian chorioallantoic membrane (CAM) model in investigations into angiogenesis. Curr Drug Targets Cardiovasc Haematol Disord 3(2):155-185
13. Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M (1997) New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 34(6):455-463
14. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63
15. Folkman J (1974) Proceedings: tumor angiogenesis factor. Cancer Res 34:2109-2113
16. Ingber DE (1992) Extracellular matrix as a solid-state regulator in angiogenesis: identiWcation of new targets for anti-cancer therapy. Semin Cancer Biol 3(2):57-63
17. Xu G, Pan J, Martin C, Yeung SJ (2001) Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86(4):1769-1777
18. Nuijen B, Bouma M, Manada C, Jimeno JM, Schellens JH, Bult A, Beijnen JH (2000) Pharmaceutical development of anticancer agents derived from marine sources. Anticancer Drugs 11(10):793-811
19. Cragg GM, Newman DJ (1999) Discovery and development of antineoplastic agents from natural sources. Cancer Invest 17(2):153-163
20. Schwartsmann G (2000) Marine organisms and other novel natural sources of new cancer drugs. Ann Oncol 11:235-243
21. Folkman J (1985) Tumor angiogenesis. Adv Cancer Res 43:175-203
22. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364
23. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404-407